India to begin first round of massive Covid vaccination programme

But concerns have been raised over the efficacy of Covaxin because the

regulator’s emergency approval came before the completion of Phase 3 clinical trials. The regulator and the manufacturer have said the vaccine is safe, and that the efficacy data would be available by February.